Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Filings indexed 1,398 across all filing types
Latest filing 2018-02-28 Declaration of Voting R…
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly states 'Publication of total number of voting rights'. It details a 'Type of capital measure' involving a 'Conditional capital increase' and provides the 'New total number of voting rights'. This type of mandatory disclosure regarding the total number of shares and voting rights, often triggered by capital changes or regulatory requirements (like Article 41 of the WpHG mentioned here), is a specific regulatory filing. Since it is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV), and it relates to the structure of capital/shares, it fits best under the general regulatory announcement category, RNS, or potentially SHA (Share Issue/Capital Change). Given the focus is on the *total voting rights* resulting from a capital measure, and it is a formal announcement distributed via DGAP (a service for regulatory announcements), RNS is the most appropriate general regulatory filing code. However, since it specifically details a capital measure affecting the share count, SHA is also highly relevant. Comparing the definitions, SHA covers 'Announcement regarding new share issues, stock splits, or other capital changes.' This document announces the result of a capital change. I will classify it as SHA due to the specific content regarding capital structure change, which is more precise than the general RNS fallback.
2018-02-28 English
Roadshow London
Investor Presentation Classification · 95% confidence The document contains extensive financial data, including 'FY/17 Highlights', detailed Profit and Loss Statements for Q4/17 and FY/17, segment growth analysis, cash flow statements, and a '2018 Financial Outlook'. The structure, detailed tables, and focus on full-year performance strongly indicate a comprehensive annual financial report or a presentation summarizing it. Since the document is a presentation ('# Roadshow London', slide format) detailing full-year results and outlook, it functions as an Investor Presentation (IP) summarizing the Annual Report data, rather than the formal 10-K filing itself. However, given the depth of the financial review ('Financial Review Q4 & FY/17'), it is more substantial than a typical Investor Presentation (IP) which often focuses on strategy. It closely resembles the content typically found in an Annual Report (10-K) or a detailed Earnings Release/Interim Report, but the context of a 'Roadshow' presentation points towards an Investor Presentation (IP) or a Management Discussion & Analysis (MDA) summary. Since it covers the full fiscal year ('FY/17') and includes detailed P&L tables, it is a comprehensive review. Given the options, 'Investor Presentation' (IP) is the best fit for a roadshow presentation summarizing full-year results, as it is a presentation format used to convey annual performance to investors. If it were the actual regulatory filing, it would be 10-K. As a presentation summarizing the full year, IP is appropriate.
2018-02-28 English
Telefonkonferenz Geschäftsergebnisse 2017, Fresenius
Investor Presentation Classification · 98% confidence The document is titled "Conference Call – FY/17 Results" and contains detailed financial highlights, segment performance breakdowns (Fresenius Kabi, Helios, Vamed), P&L statements for Q4/17 and FY/17, cash flow analysis, and a 2018 financial outlook. The content is clearly a presentation summarizing periodic financial performance and future guidance, which is typical of an earnings call presentation or a detailed investor presentation following an earnings release. Since it is a presentation format ('This presentation contains...') and provides comprehensive financial data beyond just the initial highlights, it strongly aligns with the Investor Presentation (IP) category. It is too detailed for a simple Earnings Release (ER) and is not a full transcript (CT).
2018-02-27 English
Fresenius SE & Co. KGaA: Investigation into alleged breaches of FDA data integrity requirements at Akorn, Inc.; Fresenius aims at strong growth in 2018 and confirms mid-term growth targets
Earnings Release Classification · 100% confidence The document is a news release dated February 26, 2018, titled 'Fresenius SE & Co. KGaA: Investigation into alleged breaches of FDA data integrity requirements at Akorn, Inc.; Fresenius aims at strong growth in 2018 and confirms mid-term growth targets'. It explicitly covers 'FULL YEAR 2017 RESULTS' and provides Group guidance for 2018 and mid-term targets. This content structure—announcing annual results, providing forward guidance, and discussing key operational/M&A updates (Akorn investigation)—is characteristic of an Earnings Release (ER). It is not the full 10-K, nor is it a transcript (CT) or a formal proxy statement (DEF 14A). Since it announces the results and guidance, ER is the most appropriate classification, rather than RPA, as it contains the core financial highlights, not just an announcement that a report is available. FY 2017
2018-02-26 English
Report Publication Announcement 2018
Report Publication Announcement Classification · 100% confidence The document is a preliminary announcement dated February 7, 2018, stating *when* various financial reports (Annual financial report, Group annual financial report, Group financial report (half-year/Q2)) will be disclosed in the future (March 21, 2018, and August 1, 2018). It explicitly states that the reports 'shall be disclosed' on those future dates and provides links to where they will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or is attached classifies as a Report Publication Announcement (RPA). The document itself is not the full financial report (10-K or IR), but an announcement about its publication schedule.
2018-02-07 English
Report Publication Announcement 2018
Report Publication Announcement Classification · 100% confidence The document is a very short announcement (1770 chars) dated February 7, 2018, titled 'Preliminary announcement of the publication of quarterly reports and quarterly/interim statements'. It explicitly states that it is a preliminary announcement regarding the *future* disclosure dates (May 04, 2018, and October 31, 2018) of specific financial reports (Q1 and Q3 reports). According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or timing of a report, rather than containing the report itself, should be classified as a Report Publication Announcement (RPA).
2018-02-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.